Drugs / PhytoSERM
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05664477 | Jan 2024 → Jan 2027 expected | metabolic disease | Roberta Brinton | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PhytoSERM | “This is a proof-of-concept phase 2 clinical trial to investigate the safety and effect of the phytoestrogenic supplement PhytoSERM on regional brain metabolism by fluorine-18...” NCT05664477 ↗ |
| Modality | Other / unclassified | “This is a proof-of-concept phase 2 clinical trial to investigate the safety and effect of the phytoestrogenic supplement PhytoSERM on regional brain metabolism by fluorine-18...” NCT05664477 ↗ |
| Route | Oral | “PhytoSERM or placebo pills will be administered orally once a week over 24 weeks.” NCT05664477 ↗ |